These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

424 related articles for article (PubMed ID: 8087846)

  • 1. Ubiquitin-dependent c-Jun degradation in vivo is mediated by the delta domain.
    Treier M; Staszewski LM; Bohmann D
    Cell; 1994 Sep; 78(5):787-98. PubMed ID: 8087846
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential regulation of c-Jun and JunD by ubiquitin-dependent protein degradation.
    Musti AM; Treier M; Peverali FA; Bohmann D
    Biol Chem; 1996 Oct; 377(10):619-24. PubMed ID: 8922589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phorbol esters stimulate the phosphorylation of c-Jun but not v-Jun: regulation by the N-terminal delta domain.
    Adler V; Franklin CC; Kraft AS
    Proc Natl Acad Sci U S A; 1992 Jun; 89(12):5341-5. PubMed ID: 1608942
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The v-Jun point mutation allows c-Jun to escape GSK3-dependent recognition and destruction by the Fbw7 ubiquitin ligase.
    Wei W; Jin J; Schlisio S; Harper JW; Kaelin WG
    Cancer Cell; 2005 Jul; 8(1):25-33. PubMed ID: 16023596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lysosomal localization of ubiquitinated Jun requires multiple determinants in a lysine-27-linked polyubiquitin conjugate.
    Ikeda H; Kerppola TK
    Mol Biol Cell; 2008 Nov; 19(11):4588-601. PubMed ID: 18716056
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncogenic effect of delta deletion in v-Jun does not result from uncoupling Jun from JNK signaling.
    Sprowles A; Wisdom R
    Oncogene; 2003 Jan; 22(4):498-506. PubMed ID: 12555063
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ubiquitinylation of transcription factors c-Jun and c-Fos using reconstituted ubiquitinylating enzymes.
    Hermida-Matsumoto ML; Chock PB; Curran T; Yang DC
    J Biol Chem; 1996 Mar; 271(9):4930-6. PubMed ID: 8617766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted degradation of c-Fos, but not v-Fos, by a phosphorylation-dependent signal on c-Jun.
    Papavassiliou AG; Treier M; Chavrier C; Bohmann D
    Science; 1992 Dec; 258(5090):1941-4. PubMed ID: 1470918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo viral and cellular Jun complexes exhibit differential interaction with a number of in vitro generated 'AP-1- and CREB-like' target sequences.
    Hadman M; Loo M; Bos TJ
    Oncogene; 1993 Jul; 8(7):1895-903. PubMed ID: 8510933
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nuclear translocation of viral Jun but not of cellular Jun is cell cycle dependent.
    Chida K; Vogt PK
    Proc Natl Acad Sci U S A; 1992 May; 89(10):4290-4. PubMed ID: 1584763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amino acid substitutions modulate the effect of Jun on transformation, transcriptional activation and DNA replication.
    Morgan IM; Asano M; Håvarstein LS; Ishikawa H; Hiiragi T; Ito Y; Vogt PK
    Oncogene; 1993 May; 8(5):1135-40. PubMed ID: 8479738
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SAG/ROC2/Rbx2 is a novel activator protein-1 target that promotes c-Jun degradation and inhibits 12-O-tetradecanoylphorbol-13-acetate-induced neoplastic transformation.
    Gu Q; Tan M; Sun Y
    Cancer Res; 2007 Apr; 67(8):3616-25. PubMed ID: 17440073
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phosphorylation-dependent targeting of c-Jun ubiquitination by Jun N-kinase.
    Fuchs SY; Dolan L; Davis RJ; Ronai Z
    Oncogene; 1996 Oct; 13(7):1531-5. PubMed ID: 8875991
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biochemical analysis of transcriptional activation by Jun: differential activity of c- and v-Jun.
    Bohmann D; Tjian R
    Cell; 1989 Nov; 59(4):709-17. PubMed ID: 2510934
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The avian cellular homolog of the oncogene jun.
    Nishimura T; Vogt PK
    Oncogene; 1988 Dec; 3(6):659-63. PubMed ID: 2577867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The v-Jun oncoprotein replaces p39 c-Jun as the predominant AP-1 constituent in ASV17-transformed fibroblasts: implications for SAPK/JNK-mediated signal transduction.
    Kilbey A; Black EJ; Unlu M; Gillespie DA
    Oncogene; 1996 Jun; 12(11):2409-18. PubMed ID: 8649782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanism of processing of the NF-kappa B2 p100 precursor: identification of the specific polyubiquitin chain-anchoring lysine residue and analysis of the role of NEDD8-modification on the SCF(beta-TrCP) ubiquitin ligase.
    Amir RE; Haecker H; Karin M; Ciechanover A
    Oncogene; 2004 Apr; 23(14):2540-7. PubMed ID: 14676825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential and antagonistic effects of v-Jun and c-Jun.
    Gao M; Morgan I; Vogt PK
    Cancer Res; 1996 Sep; 56(18):4229-35. PubMed ID: 8797597
    [TBL] [Abstract][Full Text] [Related]  

  • 19. v-Jun represses c-jun proto-oncogene expression in vivo through a 12-O-tetradecanoylphorbol-13-acetate-responsive element in the proximal gene promoter.
    Hussain S; Kilbey A; Gillespie DA
    Cell Growth Differ; 1998 Aug; 9(8):677-86. PubMed ID: 9716184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TOJ3, a target of the v-Jun transcription factor, encodes a protein with transforming activity related to human microspherule protein 1 (MCRS1).
    Bader AG; Schneider ML; Bister K; Hartl M
    Oncogene; 2001 Nov; 20(51):7524-35. PubMed ID: 11709724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.